Buyout Desk
Platform

Webster Equity Partners agrees to acquire Lifecore Biomedical

The pending take-private offers $6.28 per share in cash plus a contingent value right tied to milestones.

Target
Lifecore Biomedical
Buyer
Webster Equity Partners
Value
up to $663.7 million

Lifecore Biomedical has entered a definitive agreement to be acquired by an affiliate of Webster Equity Partners. Shareholders would receive $6.28 per share in cash at closing plus a non-tradable contingent value right tied to specified milestones.

The transaction remains subject to shareholder approval and other closing conditions. Lifecore is a contract development and manufacturing organization focused on injectable drug products.

The agreement includes a 30-day go-shop period during which Lifecore may consider alternative proposals. The companies announced the agreement.

Background

Business
Contract development and manufacturer of sterile injectable pharmaceuticals and injectable-grade hyaluronic acid
Deal type
Platform
Headquarters
Chaska, Minnesota

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.